Minimal Residual Disease Status as a Surrogate Endpoint for Progression-Free Survival in Newly Diagnosed Multiple Myeloma Studies: A Meta-analysis

BACKGROUND: Therapeutic advances have greatly extended survival times in patients with multiple myeloma, necessitating increasingly lengthy trials when using survival outcomes primary endpoints. A surrogate endpoint that can more rapidly predict survival could accelerate drug development. We conduct...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Clin Lymphoma Myeloma Leuk
Hlavní autoři: Avet-Loiseau, Hervé, Ludwig, Heinz, Landgren, Ola, Paiva, Bruno, Morris, Chris, Yang, Hui, Zhou, Kefei, Ro, Sunhee, Mateos, Maria-Victoria
Médium: Artigo
Jazyk:Inglês
Vydáno: 2019
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7444731/
https://ncbi.nlm.nih.gov/pubmed/31780415
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clml.2019.09.622
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky